Antitrust

Phil Davis Takes a Stand: Veteran Fighter Files Antitrust Lawsuit Against UFC, Alleges Monopolistic Practices

by

Las Vegas, Nevada — Mixed martial artist Phil Davis has filed a new lawsuit against the Ultimate Fighting Championship (UFC), alleging that the promotion engages in monopolistic practices that adversely impact fighter compensation and suppress competition in the sport. The lawsuit, submitted on Thursday in the U.S. District Court of Nevada, seeks to hold the UFC accountable for stifling rival promotions and limiting opportunities for fighters. Davis, who competed in the UFC from 2010 to 2015 before joining Bellator MMA, is represented by the law firm Berger Montague. This firm recently achieved a notable victory … Read more

California’s Antitrust Laws Set for Major Overhaul: New Proposals Target Big Tech and Enhance Competitive Practices

by

California is poised for a significant overhaul of its antitrust laws, with proposed reforms that could fundamentally reshape the regulatory landscape for businesses, especially in the technology sector. In response to evolving market conditions, the California Law Revision Commission (CLRC) has put forth recommendations developed by eight working groups, aiming to modernize state antitrust regulations. The suggested changes focus on enhancing the state’s existing framework to address the complexities introduced by digital markets, artificial intelligence, and increasing market consolidation. If implemented, the new guidelines could elevate the standards for anticompetitive practices in California, potentially surpassing … Read more

Regeneron Secures $400M Jury Victory as Amgen Faces Antitrust Liability

by

REGIONAL, USA — A federal jury delivered a significant verdict in favor of Regeneron Pharmaceuticals, awarding the company over $400 million in damages in a high-stakes antitrust case against Amgen. The jury found Amgen liable for anticompetitive conduct related to its marketing strategies for a key medication used in treating certain eye diseases. The lawsuit, which made its way to the courtroom after years of legal maneuvering, centered on Amgen’s alleged efforts to stifle competition in the market for treatments, potentially affecting thousands of patients. The jury’s decision signals a clear stance against practices that … Read more

Amgen Faces $400M+ Liability to Regeneron Following Antitrust Ruling on Cholesterol Drug

by

Amgen, a prominent biotechnology company based in Thousand Oaks, California, faces potential financial ramifications exceeding $400 million following a significant antitrust lawsuit concerning its cholesterol-lowering medication. The outcome of this legal battle could have substantial consequences for both Amgen and its competitor Regeneron Pharmaceuticals. The lawsuit, which centered on allegations of anti-competitive practices, has drawn attention to the ongoing efforts within the pharmaceutical industry to navigate regulatory frameworks while maintaining competitive pricing for consumers. The jury’s decision in favor of Regeneron underscores the legal challenges that can arise when companies seek to protect their market … Read more